Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 2009 Sep;64(4):769-75.
doi: 10.1007/s00280-009-0926-8. Epub 2009 Jan 24.

Fotemustine as second-line treatment for recurrent or progressive glioblastoma after concomitant and/or adjuvant temozolomide: a phase II trial of Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO)

Alba A Brandes  1 , A Tosoni, E Franceschi, V Blatt, A Santoro, M Faedi, P Amistà, M Gardiman, R Labianca, C Bianchini, M Ermani, M Reni
Affiliations
Clinical Trial

Fotemustine as second-line treatment for recurrent or progressive glioblastoma after concomitant and/or adjuvant temozolomide: a phase II trial of Gruppo Italiano Cooperativo di Neuro-Oncologia (GICNO)

Alba A Brandes et al. Cancer Chemother Pharmacol. 2009 Sep.

Abstract

Background: Standardized salvage treatment has not yet proved effective in glioblastoma multiforme (GBM) patients who receive prior standard radiotherapy plus concomitant and adjuvant temozolomide.

Methods: Patients with progressive GBM after radiotherapy plus concomitant and/or adjuvant temozolomide received three-weekly doses (100-75 mg m(2)) of fotemustine followed, after a 5-week rest, by fotemustine (100 mg m(2)) every 3 weeks for < or =1 year.

Results: Forty-three patients (29 M, 14 F; median age 51 years, range 34-68; median KPS 90) were enrolled. Progression-free survival at 6 months (PFS-6) was 20.9% (95% CI: 9-33%); three patients (7.1%) had partial response (PR); 15 (34.9%), disease stabilization (SD). The median survival was 6 months (95% CI: 5-7). MGMT promoter status was methylated in 8 (18.6%) and unmethylated in 26 (60.5%) and not assessable in 9 (20.9%) patients, respectively. Disease control was 75% versus 34.6% in methylated and unmethylated MGMT patients (P = 0.044); no significant difference was found between groups for PFS-6 and survival. Grade 3 and 4 thrombocytopenia and neutropenia were observed in 20.9 and 16.3% of patients, during the induction phase, and in 0 and 9.5% patients during the maintenance phase, respectively.

Conclusions: The findings of the present trial, that evaluate fotemustine in a homogeneous population, may represent a new benchmark for nitrosourea activity. Moreover, this is the first study to evaluate correlation between MGMT promoter status and outcome of fotemustine for relapsing GBM previously treated with radiotherapy and temozolomide.

PubMed Disclaimer

References

    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1200/JCO.2004.04.165', 'is_inner': False, 'url': 'https://doi.org/10.1200/jco.2004.04.165'}, {'type': 'PubMed', 'value': '15020614', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/15020614/'}]}
    2. Avril MF, Aamdal S, Grob JJ, Hauschild A, Mohr P, Bonerandi JJ, Weichenthal M, Neuber K, Bieber T, Gilde K, Guillem Porta V, Fra J, Bonneterre J, Saiag P, Kamanabrou D, Pehamberger H, Sufliarsky J, Gonzalez Larriba JL, Scherrer A, Menu Y (2004) Fotemustine compared with dacarbazine in patients with disseminated malignant melanoma: a phase III study. J Clin Oncol 22:1118–1125 - PubMed
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.2174/1381612013397221', 'is_inner': False, 'url': 'https://doi.org/10.2174/1381612013397221'}, {'type': 'PubMed', 'value': '11562299', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/11562299/'}]}
    2. Brandes AA, Basso U, Pasetto LM, Ermani M (2001) New strategy developments in brain tumor therapy. Curr Pharm Des 7:1553–1580 - PubMed
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'PubMed', 'value': '15477552', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/15477552/'}]}
    2. Brandes AA, Tosoni A, Amista P, Nicolardi L, Grosso D, Berti F, Ermani M (2004) How effective is BCNU in recurrent glioblastoma in the modern era? A phase II trial. Neurology 63:1281–1284 - PubMed
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1038/sj.bjc.6603376', 'is_inner': False, 'url': 'https://doi.org/10.1038/sj.bjc.6603376'}, {'type': 'PMC', 'value': 'PMC2360560', 'is_inner': False, 'url': 'https://pmc.ncbi.nlm.nih.gov/articles/PMC2360560/'}, {'type': 'PubMed', 'value': '17024124', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/17024124/'}]}
    2. Brandes AA, Tosoni A, Cavallo G, Bertorelle R, Gioia V, Franceschi E, Biscuola M, Blatt V, Crino L, Ermani M (2006) Temozolomide 3 weeks on and 1 week off as first-line therapy for recurrent glioblastoma: phase II study from gruppo italiano cooperativo di neuro-oncologia (GICNO). Br J Cancer 95:1155–1160 - PMC - PubMed
    1. {'text': '', 'ref_index': 1, 'ids': [{'type': 'DOI', 'value': '10.1002/cncr.20611', 'is_inner': False, 'url': 'https://doi.org/10.1002/cncr.20611'}, {'type': 'PubMed', 'value': '15372474', 'is_inner': True, 'url': 'https://pubmed.ncbi.nlm.nih.gov/15372474/'}]}
    2. Brandes AA, Tosoni A, Vastola F, Pasetto LM, Coria B, Danieli D, Iuzzolino P, Gardiman M, Talacchi A, Ermani M (2004) Efficacy and feasibility of standard procarbazine, lomustine, and vincristine chemotherapy in anaplastic oligodendroglioma and oligoastrocytoma recurrent after radiotherapy. A Phase II study. Cancer 101:2079–2085 - PubMed

Publication types

MeSH terms